NEW YORK, Oct. 4, 2011 /PRNewswire/ -- Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine, today announced the appointment of David Okrongly, Ph.D., as chief operating officer, Michael Donovan, M.D., Ph.D., as chief medical officer, and Sally Bowden, Ph.D., as director of regulatory affairs. Raphael Bueno, M.D., associate chief of cardiothoracic surgery Harvard University and Michael Manyak, M.D., FACS, executive director global medical affairs at GlaxoSmithKline were named to the Scientific Advisory Board.
The hiring of Drs. Okrongly, Donovan and Bowden reflect the Company's expanded research and clinical validation program for its proprietary exosome RNA biofluid technology in oncology diagnostics. Exosome Diagnostics is applying the stable RNA content of blood and urine exosomes to develop in-vitro diagnostics for transcriptional disease profiling, patient stratification and disease monitoring in prostate cancer, melanoma and other cancers.
"The collective professional experiences of Drs. Okrongly, Donovan and Bowden are invaluable management additions as we expand clinical studies for our lead exosome biofluid RNA diagnostics," said chief executive officer James McCullough. "The addition of Dr. Bueno and Dr. Manyak to our Scientific Advisory Board builds on our strategy of working closely with top clinical investigators to more accurately assess how exosome technology can be best applied to address unmet medical needs."
Dr. Okrongly has significant experience developing and commercializing advanced diagnostic platforms. Dr. Okrongly was president and chief executive officer of Quanterix from August 2009 to May 2011, leading the company in development of the first fully automated, single-molecule diagnostic platform with 1,000 times better sensitivity than ELISA. From May 1997 to December 2006, Dr. Okrongly was with Bayer Diag
|SOURCE Exosome Diagnostics|
Copyright©2010 PR Newswire.
All rights reserved